Register
Login

Trending Topic

2 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

From advances in targeted therapies to the integration of AI and steps towards precision medicine, 2024 brought many exciting developments in the field. With 2025 now unfolding, many of these are likely to continue gaining momentum and potentially redefine patient care. In this latest edition of touchREVIEWS in RMD, we’re excited to present a collection […]

Andy Blauvelt: Switching from Dupilumab to Upadacitinib in Atopic Dermatitis

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Oct 5th 2021

Touch Medical Media coverage of data presented at EADV 2021:

It was a pleasure to speak with Dr Andy Blauvelt (Oregon Medical Research Center, Portland, OR, USA) about the results from the recent open-label study investigating the efficacy and safety of switching from dupilumab to upadacitinib in the treatment of atopic dermatitis.

His presentation entitled ‘Efficacy and Safety of Switching from Dupilumab to Upadacitinib in Moderate-to-Severe Atopic Dermatitis: Results from an Open Label Extension Trial’ was given at the EADV 30th Congress, 29 Sep – 2 Oct.

Questions

  1. Could you give us a brief overview of dupilumab and upadacitinib, their mechanisms of action and their means of administration? (0:15)
  2. What is the rationale for switching from dupilumab to upadacitinib in the treatment of moderate-to-severe atopic dermatitis? (1:26)
  3. Could you tell us a little about the methodology of your clinical trial? (2:15)
  4. What were the findings of the open-label extension study and what are their clinical implications? (2:55)
  5. How likely is it in the future that upadacitinib will replace dupilumab as first-line treatment of moderate-to-severe atopic dermatitis? (4:23)

Disclosures: Dr Andy Blauvelt has served as a scientific adviser and/or clinical study investigator for AbbVie, Abcentra, Aligos, Almirall, Amgen, Arcutis, Arena, Aslan, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Eli Lilly and Company, Evommune, Forte, Galderma, Incyte, Janssen, Landos, Leo, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma, UCB Pharma, and Vibliome.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Matthew Goodwin.

Filmed in coverage of the EADV’s 30th Congress, 29 Sep – 2 Oct 2021.

This content was developed by Touch Medical Media and is not affiliated with the  European Academy of Dermatology & Venereology  (EADV) or the congress. 

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup